Roundup: Johnson & Johnson COVID-19 vaccine 66 percent effective in preventing moderate to severe COVID-19: study

WASHINGTON, Jan. 29 (Xinhua) -- Johnson & Johnson's COVID-19 vaccine candidate was 66 percent effective overall in preventing moderate to severe COVID-19, 28 days after vaccination, the company announced on Friday.

The result was based on the Phase 3 ENSEMBLE study involving nearly 44,000 participants. The study, designed to evaluate the efficacy and safety of the vaccine candidate in protecting moderate to severe COVID-19, was conducted in the United States, Latin America and South Africa.